Monica Granucci
YOU?
Author Swipe
View article: Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases Open
View article: BSBM-12 IDENTIFYING A NOVEL GENE SIGNATURE FOR PREDICTING BRAIN METASTASIS RISK IN BREAST CANCER USING SPATIAL TRANSCRIPTOMICS
BSBM-12 IDENTIFYING A NOVEL GENE SIGNATURE FOR PREDICTING BRAIN METASTASIS RISK IN BREAST CANCER USING SPATIAL TRANSCRIPTOMICS Open
BACKGROUND Up to 50% of patients with advanced-stage breast cancer develop brain metastases (BrMets), a diagnosis associated with a median survival of just 10 months and significant neurologic decline. However, BrMet risk is not uniform am…
View article: Spatial Profiling Reveals Equivalence-Derived Molecular Signatures of Brain Mimicry and Adaptation in Breast Cancer Brain Metastases
Spatial Profiling Reveals Equivalence-Derived Molecular Signatures of Brain Mimicry and Adaptation in Breast Cancer Brain Metastases Open
Brain metastases (BrMets), common for advanced-stage breast cancer patients, are associated with poor median survival and accompanied by severe neurologic decline. Halting the progression of breast cancer brain metastases (BCBMs) may requi…
View article: Monitoring of cancer ferroptosis with [<sup>18</sup>F]hGTS13, a system xc- specific radiotracer
Monitoring of cancer ferroptosis with [<sup>18</sup>F]hGTS13, a system xc- specific radiotracer Open
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults, characterized by resistance to conventional therapies and poor survival. Ferroptosis, a form of regulated cell death driven by lipid peroxidatio…
View article: Brain Metastases from Esophageal Cancer: A Retrospective Review from a Single Institution
Brain Metastases from Esophageal Cancer: A Retrospective Review from a Single Institution Open
View article: TMIC-75. SPATIALLY-RESOLVED TRANSCRIPTOME ANALYSIS OF BRAIN METASTATIC BREAST CANCER REVEAL KEY MEDIATORS OF BRAIN-TROPIC METASTATIC POTENTIAL
TMIC-75. SPATIALLY-RESOLVED TRANSCRIPTOME ANALYSIS OF BRAIN METASTATIC BREAST CANCER REVEAL KEY MEDIATORS OF BRAIN-TROPIC METASTATIC POTENTIAL Open
BACKGROUND In women with metastatic breast cancer, 30% (HER2+) to 50% (triple negative) develop brain metastases. Breast-to-brain metastasis carries a poor median survival of only 10 months and is accompanied by severe neurologic decline. …
View article: BSBM-17 NOVEL VALIDATED PATIENT-DERIVED MODELS OF A RECTAL CANCER BRAIN METASTASIS
BSBM-17 NOVEL VALIDATED PATIENT-DERIVED MODELS OF A RECTAL CANCER BRAIN METASTASIS Open
Colorectal adenocarcinomas (CRC) rarely metastasize to the brain, however, survival rates in patients with colorectal brain metastases (CBM) are short, with a median survival of only 4 months from diagnosis. Currently, no evidence-based tr…
View article: Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
View article: Supplementary Figure S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Post-therapy Imaging of IC-1
View article: Supplementary Table S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Vital signs of the patients administered with [18F]DASA-23
View article: Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Comparative metabolic PET/CT imaging in U87-GFP/luc GBM mice
View article: Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Comparative metabolic PET/CT imaging in U87-GFP/luc GBM mice
View article: Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in healthy volunteers
View article: Supplementary Figure S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 Radiosynthesis
View article: Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-2
View article: Supplementary Table S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Clinical Characteristics of patients imaged with [18F]DASA-23
View article: Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-2
View article: Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
View article: Data from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Data from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Purpose:Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain. We describe the developmen…
View article: Supplementary Figure S7 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S7 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
PKM2 analysis in TP459 neurospheres
View article: Supplementary Figure S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Western blot analysis of PKM2 expression in IC-1
View article: Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Hematology laboratory testing results of patients imaged with [18F]DASA-23
View article: Supplementary Figure S9 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S9 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-3
View article: Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Hematology laboratory testing results of patients imaged with [18F]DASA-23
View article: Supplementary Table S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Blood chemistry laboratory testing results of the patients imaged with [18F]DASA-23
View article: Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in brain tumor patients
View article: Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in brain tumor patients
View article: Supplementary Figure S10 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S10 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-4
View article: Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in healthy volunteers
View article: Supplementary Figure S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 time activity curves